King Pharmaceuticals LLC research and develops, manufactures, markets, and sells prescription pharmaceutical products and animal health products worldwide. It offers branded prescription pharmaceuticals, which include neuroscience products, such as Skelaxin, Flector Patch, Avinza, and Embeda; hospital products, including Thrombin-JMI; and legacy products consisting of Levoxyl, Bicillin, Altace, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. The company’s animal health business focuses on medicated feed additives and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, ...
501 Fifth Street
Bristol, TN 37620
Founded in 1993
King Pharmaceuticals LLC to Pay $2.2 Million Civil Penalty
Jun 29 13
King Pharmaceuticals LLC will pay $2.2 million and take measures to comply with the Clean Air Act to resolve alleged violations of the Clean Air Act (CAA) at its pharmaceutical manufacturing facility located in Bristol, Tenn., announced the Department of Justice, the U.S. Environmental Protection Agency (EPA), and the Tennessee Department of Environment and Conservation (TDEC). From the $2.2 million civil penalty, $1.1 million will be paid to the United States and $1.1 million will be paid to TDEC. From TDECs $1.1 million penalty, $650,000 will be applied to a TDEC state project for homeowners. The settlement also requires the facility to demonstrate compliance with CAA National Emission Standards for Pharmaceuticals Production (PharmaMACT regulations) and to apply for a Title V permit.